Dianthus Therapeutics (NASDAQ:DNTH) versus Zura Bio (NASDAQ:ZURA) Head to Head Analysis

Zura Bio (NASDAQ:ZURA) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zura Bio and Dianthus Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1	0	5	1	2.86
Dianthus Therapeutics	1	0	12	1	2.93

Zura Bio presently has a consensus target price of $17.00, suggesting a potential upside of 193.61%. Dianthus Therapeutics has a consensus target price of $124.27, suggesting a potential upside of 10.05%. Given Zura Bio’s higher probable upside, equities analysts clearly believe Zura Bio is more favorable than Dianthus Therapeutics.

Profitability

This table compares Zura Bio and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Insider & Institutional Ownership

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Valuation & Earnings

This table compares Zura Bio and Dianthus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35 million	($1.13)	-5.12
Dianthus Therapeutics	$2.04 million	3,026.39	-$162.34 million	($4.15)	-27.21

Zura Bio has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Zura Bio beats Dianthus Therapeutics on 7 of the 13 factors compared between the two stocks.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.